A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
The main objective of this clinical trial represents the evaluation of efficacy of the tyrosine kinase inhibitor Cabozantinib in patients with NEN G3 with a proliferation rate of Ki67 20 - 60%.
Neuroendocrine Tumors|Neuroendocrine Carcinoma
DRUG: Cabozantinib
Evaluate the efficacy of Cabozantinib treatment via DCR after 6 months., Disease control rate (DCR) 6 months after treatment start ., 6 months
Evaluate short- and long term efficacy of Cabozantinib treatment via DCR., DCR 3 and 12 months after treatment start., 12 months|Evaluate short- and long term efficacy of Cabozantinib treatment via ORR., Objective response rate (ORR) 3, 6 and 12 months after treatment start and best objective response rate., 12 months|Evaluate short- and long term efficacy of Cabozantinib treatment via PFS., Progression free survival (PFS)., 24 months|Evaluate short- and long term efficacy of Cabozantinib treatment via OS., Overall survival (OS)., 24 months|Evaluate exposure time., Time on drug (TOD)., 12 months|Assess quality-of-life during and after Cabozantinib treatment., EORTC QLQ-C30 Quality of Life Questionnaire monthly for 12 months after treatment start and after 15 months. Different questions regarding Quality of Life on a scale of 1 - 4. The lower the numbers, the better the quality of Life., 15 months
Safety of Cabozantinib via AE and SAE assessment., Adverse events and serious adverse events will be assessed in contingency tables., 24 months
The main objective of this clinical trial represents the evaluation of efficacy of the tyrosine kinase inhibitor Cabozantinib in patients with NEN G3 with a proliferation rate of Ki67 20 - 60%.